Literature DB >> 18497072

Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk.

Herbert I Jacobson1, Nicole Lemanski, Amithi Narendran, Anu Agarwal, James A Bennett, Thomas T Andersen.   

Abstract

Parity profoundly reduces breast cancer (BC) risk later in life. It has been reasoned that hormones (either estradiol E2 or estriol E3), progesterone (P) or human chorionic gonadotropin (hCG) in the serum of pregnant women might lead to that reduction in risk. These agents have been shown to reduce BC incidence in nonpregnant rats. We investigated the hypothesis that exogenously added E2, E3, P, or hCG are not the proximal effectors of risk reduction, but that they elicit alpha-fetoprotein (alphaFP) from the nonpregnant liver, and that cFP is the proximal agent by which reduction of BC risk is obtained. Methylnitrosourea (MNU)-exposed animals were treated with saline, E3, E2 + P, E3 + P, hCG, or were allowed to experience pregnancy, and AFP levels were measured in the serum and subsequent tumor incidence was recorded. Human HepG2 liver cells in culture were treated with E3, E2 + P, P, or hCG and elicited AFP was measured in the media. The HepG2 culture media containing elicited AFP was assessed for its ability to inhibit proliferation of T47D cells when applied to these human BC cells in culture, and to inhibit the estrogen-induced phosphorylation of the estrogen receptor in T47D cells. For each condition in the prevention studies, hormone treatment reduced the incidence of BC to an extent similar to that reported by the original studies. In each condition, alphaFP levels in serum were elevated over that in control animals. In culture, treatment of human liver cells with E3, E2 + P, or hCG, but not P alone, led to increased levels of AFP in the media. Media containing hCG-elicited AFP inhibited the estrogen-stimulated proliferation of T47D cells in culture, and inhibited phosphorylation of the estrogen receptor, whereas, estrogens and hCG did not inhibit the growth of these tumor cells in culture. In conclusion, since the hormones of pregnancy elicit alphaFP from the liver, and alphaFP but not the hormones of pregnancy has direct antitumor properties, it is concluded that alphaFP is the proximal agent through which reduction in BC incidence is realized from the experience of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497072     DOI: 10.1007/978-0-387-69080-3_47

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature.

Authors:  Sarah Nechuta; Nigel Paneth; Ellen M Velie
Journal:  Cancer Causes Control       Date:  2010-03-12       Impact factor: 2.506

Review 2.  Estrogen action: a historic perspective on the implications of considering alternative approaches.

Authors:  Elwood V Jensen; Herbert I Jacobson; Alicia A Walf; Cheryl A Frye
Journal:  Physiol Behav       Date:  2009-09-06

3.  Low salivary testosterone levels in patients with breast cancer.

Authors:  Constantine Dimitrakakis; David Zava; Spyros Marinopoulos; Alexandra Tsigginou; Aris Antsaklis; Rebecca Glaser
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

4.  Do reproductive factors influence T, N, and M classes of ductal and lobular breast cancers? A nation-wide follow-up study.

Authors:  Seyed Mohsen Mousavi; Asta Försti; Kristina Sundquist; Kari Hemminki
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

5.  Impact of Screening on Breast Cancer Incidence in Kazakhstan: Results of Component Analysis.

Authors:  Assem Toguzbayeva; Zhansaya Telmanova; Arman Khozhayev; Aizhan Jakipbayeva; Gulshara Aimbetova; Akmaral Zhantureyeva; Zarina Bilyalova; Saltanat Urazova; Gulnur Igissinova; Botagoz Turdaliyeva; Malcolm Anthony Moore; Nurbek Saginbekovich Igissinov
Journal:  Asian Pac J Cancer Prev       Date:  2021-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.